ZedScan™ Expands Presence in Finland

Monday 18th February 2019

Oulu University Hospital (OYS), which is responsible for healthcare in Northern Finland, is the latest hospital to adopt a unique adjunctive cervical cancer diagnostic device, ZedScan™, into their colposcopy practice.

As Finland move towards national primary HPV screening, the associated increase in referrals to colposcopy will impact on clinic capacity with many patients having low grade or negative cytology. This cohort of patients is the most challenging for visual diagnosis as the changes are less apparent. Real world data shows that ZedScan is consistently detecting more high-grade disease (HGCIN) than colposcopy alone, with a Health Technology Assessment in Helsinki showing a 50% increase in the detection of disease in the low-grade cohort; disease which may have been missed without ZedScan.

Following the adoption of ZedScan at Helsinki University Hospital, the positive impact on their colposcopy services led Dr Marja Simojoki, lead clinician at OYS, to bring the technology to her hospital. OYS is the second university hospital to adopt ZedScan and currently sees around 800 patient referrals to colposcopy each year. With numbers expected to increase with the expansion of their services and a planned move to primary HPV testing, the adoption of ZedScan™ will give clinicians additional information to better manage their patients.

The ZedScan device uses Electrical Impedance Spectroscopy (EIS) technology to identify cell changes that cannot always be seen during standard colposcopy practice.

By accurately detecting cell changes and minimising colposcopic subjectivity, ZedScan reassures clinicians to treat patients at first visit or return them to routine re-call when there is no high-grade disease present. This can help manage patient throughput and reduces the need for unnecessary follow-up appointments.

Cervical cancer is the 4th leading cause of cancer related deaths in Finland for women aged 15-44 years. Since 1990, the incidence of cervical cancer in Finland has risen significantly among women under 40, with more than a third of cervical cancer diagnosis resulting in loss of life.